

UNIVERSIDADE DE UBERABA  
MESTRADO EM ODONTOLOGIA  
MARISSA OLIVEIRA SILVA

**BALANÇO IMUNORREGULATÓRIO DE CÉLULAS TH1 NO SANGUE, FÍGADO E RIM  
DE RATOS NORMOGLICÊMICOS E DIABÉTICOS COM PERIODONTITE APICAL**

UBERABA – MG

2023

MARISSA OLIVEIRA SILVA

**BALANÇO IMUNORREGULATÓRIO DE CÉLULAS TH1 NO SANGUE, FÍGADO E RIM  
DE RATOS NORMOGLICÊMICOS E DIABÉTICOS COM PERIODONTITE APICAL**

Projeto de pesquisa apresentado ao Programa de Pós-Graduação em Odontologia - Mestrado Acadêmico da Universidade de Uberaba, como requisito para obtenção do título de Mestre em Odontologia, na Área de Concentração Clínica Odontológica Integrada.

Orientadora: Prof. Dra. Renata Oliveira Samuel

UBERABA – MG

2023

## DEDICATÓRIA

À Deus, em primeiro lugar sempre, sem Ele nada sou.

Aos meus pais, Eliana e Gilmar, pois de nada adiantaria minha caminhada se vocês não tivessem me ensinado os primeiros passos. Em todo o percurso, vocês estiveram presentes, mostrando-me a importância do estudo para ser uma excelente profissional.

Ao meu namorado Leonardo pelo apoio, compreensão, amor e incentivo sempre.

À todos os meus familiares que me incentivaram a vencer os desafios.

## **AGRADECIMENTO ESPECIAL**

À minha orientadora Profa. Dra. Renata Oliveira Samuel a quem devo agradecer pela amizade, carinho e a confiança na realização do trabalho. Seus ensinamentos, seus conselhos, sua capacidade intelectual e principalmente sua clareza nas orientações sempre foi fator importante durante o período de construção desse trabalho. Para sempre serei grata ao seu apoio e cultivarei intenso respeito e admiração.

Muito Obrigada!

## AGRADECIMENTOS

A Universidade de Uberaba, por meio do Reitor Prof. Dr. Marcelo Palmério.

A Pró-reitoria de Pesquisa, Pós-graduação e Extensão por meio do Pró-Reitor Prof. Dr. André Luís Teixeira Fernandes.

À Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) pela concessão da bolsa de estudo.

Aos Professores do Mestrado, minha eterna gratidão pelo apoio e pelos ensinamentos.

Aos colegas do curso de Mestrado pela convivência e as experiências trocadas.

A secretaria do curso de pós-graduação e extensão Flávia Michele da Silva pela prontidão em atender.

A todos os funcionários da Universidade Uberaba agradeço pelo trabalho executado.

A todos aqueles que de alguma forma contribuíram para que esta dissertação pudesse ser realizada.

Enfim, a todos o meu muito obrigada!

Silva, Marissa Oliveira. **Balço imunorregulatório de células Th1 no sangue, fígado e rim de ratos normoglicêmicos e diabéticos com periodontite apical.** 2023. Dissertação de mestrado – Universidade de Uberaba, Uberaba 2023.

## RESUMO

O objetivo deste estudo foi avaliar a influência da diabetes e/ou periodontite apical (PA) nos níveis de TNF- $\alpha$  e IL-6 nos tecidos hematológico, hepático e renal de ratos Wistar. Quarenta ratos machos foram divididos em quatro grupos: ratos normoglicêmicos (N), ratos normoglicêmicos com PA (N-AP), ratos com diabetes experimental (DE), ratos com diabetes experimental e periodontite apical (ED-AP). A diabetes foi induzida por injeção de estreptozotocina. O controle glicêmico foi realizado para confirmar o desenvolvimento da doença no sexto e último dia do período experimental. A infecção endodôntica foi induzida pela exposição do primeiro molar superior direito ao meio bucal. Após 30 dias, fragmentos de rim e fígado foram obtidos, bem como sangue venoso para quantificar os níveis de TNF- $\alpha$  e IL-6 pela técnica de captura de ELISA. Os valores obtidos foram tabulados e analisados estatisticamente por meio dos testes de análise de variância (ANOVA) e teste de Tukey ( $p < 0,05$ ). Os resultados mostraram níveis séricos de TNF- $\alpha$  aumentados no grupo N-AP quando comparado ao grupo N ( $p < 0,05$ ). Além disso, AP potencializou os níveis de IL-6 no fígado de ratos no grupo ED-AP quando comparado ao grupo N-AP ( $p < 0,05$ ). Entre os ratos diabéticos, o AP não alterou os níveis de TNF- $\alpha$  e IL-6 no plasma, nos tecidos renal e hepático ( $p > 0,05$ ). Além disso, o ED aumentou os níveis de TNF- $\alpha$  e IL-6 no plasma e no tecido renal quando comparado com ratos normoglicêmicos ( $p < 0,05$ ). Pode-se concluir que a AP pode promover alterações sistêmicas inflamatórias como o aumento dos níveis séricos de TNF- $\alpha$  e potencializar a produção de IL-6 em tecidos hepáticos de ratos diabéticos. Além disso, a diabetes pode aumentar os níveis de IL-6 e TNF- $\alpha$  no plasma e tecido renal.

Palavras-chave: Periodontite Periapical, Diabetes, IL-6, TNF-  $\alpha$

**Silva, Marissa Oliveira. Immunoregulatory balance of Th1 cells in blood, liver and kidney of normoglycemic and diabetic rats with apical periodontitis. 2023. Master's dissertation – University of Uberaba, Uberaba 2023.**

## **ABSTRACT**

The aim of this study was to evaluate the influence of diabetes and/or apical periodontitis (AP) in TNF- $\alpha$  and IL-6 levels in the hematologic, hepatic and renal tissues of Wistar rats. Forty male rats were divided into four groups: normoglycemic rats (N), normoglycemic rats with AP (N-AP), rats with experimental diabetes (ED), rats with experimental diabetes and apical periodontitis (ED-AP). Diabetes was induced by injection of streptozotocin. Glycemic control was performed to confirm the development of the disease at the sixth and last day of the experimental period. The endodontic infection was induced by exposure of the upper right first molar to the oral environment. After 30 days, fragments of kidney and liver were obtained, as well as venous blood to quantify TNF- $\alpha$  and IL-6 levels by ELISA capture technique. The values obtained were tabulated and analyzed statistically by means of two way analysis of variance tests (ANOVA) and Tukey test ( $p < 0.05$ ). The results showed increased TNF- $\alpha$  serum levels in the group N-AP when compared to the group N ( $p < 0.05$ ). Moreover, AP potencialized IL-6 levels in rat's liver in the group ED-AP when compared to the group N-AP ( $p < 0.05$ ). In diabetic rats, AP did not alter the levels of TNF- $\alpha$  and IL-6 in the plasm, renal and hepatic tissues ( $p > 0.05$ ). Furthermore, ED increased the TNF- $\alpha$  and IL-6 levels in plasm and renal tissue when compared with N rats ( $p < 0.05$ ). It may be concluded that AP may promote inflammatory systemic alterations as the increase of TNF- $\alpha$  serum levels and the pontencialize the IL-6 production in hepatic tissues of diabetic rats. In addition, the presence of diabetes may increase the levels of IL-6 and TNF- $\alpha$  in the plasm and renal tissue.

**Key words:** apical periodontitis, diabetes, IL-6, TNF- $\alpha$

## LISTA DE TABELAS

**Tabela 1.** TNF- $\alpha$  and IL-6 levels in hepatic and renal tissues and plasm. Different letters indicate significant statistical differences in the columns ( $p < 0.05$ ).



## LISTA DE FIGURAS

**Figura 1.** TNF- $\alpha$  levels in hepatic and renal tissues and plasm.

**Figura 2.** IL-6 levels in hepatic and renal tissues and plasm.

## SUMÁRIO

<b>RESUMO</b>	<b>V</b>
<b>ABSTRACT</b>	<b>VI</b>
<b>INTRODUÇÃO</b>	<b>11</b>
<b>PROPOSIÇÃO</b>	<b>14</b>
<b>ABSTRACT</b>	<b>17</b>
<b>INTRODUCTION</b>	<b>18</b>
<b>METHODS</b>	<b>19</b>
<b>STATISTICAL ANALYSIS</b>	<b>21</b>
<b>RESULTS</b>	<b>22</b>
<b>DISCUSSION</b>	<b>23</b>
<b>ACKNOWLEDGMENTS</b>	<b>25</b>
<b>REFERENCES</b>	<b>26</b>
<b>TABELA</b>	<b>32</b>
<b>FIGURA</b>	<b>33</b>
<b>ANEXOS</b>	<b>34</b>

## INTRODUÇÃO

A inter-relação entre o impacto da infecção oral e a saúde sistêmica é um tema que já foi amplamente estudado na história da medicina (Hunter, 1900, Billings, 1914, Rosenow, 1928). A partir da comprovação da presença de bactérias na cavidade bucal por Miller, em 1890, vários pesquisadores começaram a relacionar infecções dentárias com prejuízos sistêmicos (Hunter, 1900, Billings, 1914, Rosenow, 1928). O tema era conhecido como ‘teoria da infecção focal’ (Mills, 1913).

Em meados da década de 40, era comum pesquisas e relatos de casos clínicos de cura de diversas doenças após extrações dentárias (Hunter, 1900, Billings, 1914, Price, 1925, Rosenow, 1928). O conceito de que a boca era um foco de doenças como esquizofrenia, artrite, alopecia, dentre tantas outras se popularizou. Era comum, nesta época, pessoas se submeterem a extrações múltiplas com o objetivo de prevenir ou tratar doenças (Hunter, 1900, Billings, 1914, Price, 1925, Rosenow, 1928).

A partir da década de 50, a teoria da infecção focal começou a ser desacreditada, uma vez que foi observado que pacientes que extraíam os dentes muitas vezes não tinham a cura de doenças (Easlick, 1951). Além disso, tanto pacientes com dentição saudável como pacientes com problemas dentários desenvolviam processos patológicos. Outro problema comum na época era o desenvolvimento de outros distúrbios gástricos decorrentes da ausência dos dentes, como a dispepsia (Vaizey, Clark-Kennedy, 1939).

O tema gerou tantos problemas na comunidade médico-odontológica, que ficou esquecido por muitos anos. No entanto, na década de 90, outras pesquisas começaram a relacionar novamente a possível relação entre infecções periodontais e a saúde sistêmica (Genco, Löe, 1993; Clarke, Hirsch, 1995). Só que desta vez as pesquisas eram mais minuciosas e a proposta não era tão radical como antes. As pesquisas começaram a evidenciar que pacientes com doença periodontal descontrolada tinham mais propensão a ter piora de quadro de algumas doenças autoimunes, tais como diabetes, lúpus, psoríase, doenças cardiovasculares, entre outras (Genco, Löe, 1993; Clarke, Hirsch, 1995). No entanto, desta vez, concebeu-se que a possível relação entre as infecções orais e a saúde sistêmica não se

dá somente pela liberação de bactérias via corrente sanguínea. Na verdade, foi observado que esta relação é bidirecional, ou seja, a doença periodontal pode interferir na patogênese de doenças autoimunes assim como doenças autoimunes podem interferir na patogênese da doença periodontal. E foi consolidado que esta relação ocorre, na maioria das vezes, não pela simples presença de bactérias, mas sim pela ativação de células e mediadores inflamatórios comuns tanto nas infecções locais como em doenças sistêmicas (Prabhu *et al.* 1996). As vias biológicas para potencializar estas doenças são as mesmas. Assim, em um paciente com diabetes descompensada, por exemplo, haverá grande liberação de mediadores inflamatórios no sangue e, conseqüentemente, onde existir outro foco de infecção, como a doença periodontal, a resposta do organismo será mais exacerbada (Prabhu *et al.* 1996).

Neste contexto, milhares de estudos já deixaram bem clara a relação entre a infecção periodontal e a saúde sistêmica. No entanto, a abordagem agora diverge da abordagem do passado. Antes, para se evitar os possíveis problemas sistêmicos de alterações bucais, era indicada a extração dentária (Hunter, 1900, Billings, 1914, Price, 1925, Rosenow, 1928). Hoje, está comprovado que o tratamento e acompanhamento do paciente já traz benefícios no controle das doenças potencializadas pela periodontite (Sanz *et al.* 2018). Isso contribui para uma visão mais holística do paciente na Odontologia: a boca faz parte da manutenção de saúde do indivíduo.

No entanto, estudos relacionando a infecção endodôntica com a saúde sistêmica só surgiram recentemente. Antes, era mais comum estudos relacionando infecções endodônticas com casos pontuais de endocardites e abscessos esporádicos. Ainda há lacunas para preencher quanto aos mediadores inflamatórios liberados e possível semelhança com o impacto que a doença periodontal traz para saúde sistêmica. Sabe-se que tanto a doença periodontal como a infecção endodôntica possuem semelhanças, tais como a presença de bactérias gram positivas e negativas, a liberação de células e mediadores inflamatórios em comum que geram, como conseqüência, a reabsorção óssea (Gazivoda *et al.* 2009, Ogle, 2017).

É muito comum pacientes com infecções endodônticas permanecerem com periodontites apicais por muitos anos sem tratamento devido a ausência de dor. No entanto, manter este processo infeccioso pode ser prejudicial. Na patogênese da lesão apical são

liberadas células inflamatórias, tais como linfócitos, que possuem diferentes linhagens, que tem como consequência, a ativação de citocinas pró e anti-inflamatórias. Os linfócitos T helper 1 (Th1) atuam na liberação de citocinas pró-inflamatórias. Quanto maior a quantidade de linfócitos Th1, maior será a liberação de interleucinas (IL), fator de necrose tumoral alfa (TNF- $\alpha$ ), dentre outras citocinas que, de forma geral, tem a função de “ativar a inflamação” tanto na patogênese local da infecção, como em regiões distantes do local de origem. A ativação da inflamação localmente na periodontite apical, pode levar, por exemplo, a maior atividade osteoclástica, aumentando a reabsorção óssea da região (Marçal *et al.* 2010; Azuma *et al.* 2014). Por outro lado, estes mediadores podem atuar também de forma sistêmica, ativando processos inflamatórios em locais que já exista uma pré-disposição para tal (Azuma *et al.* 2017).

A diabetes é uma das doenças que pode ser afetada em um organismo em que haja maior liberação destes mediadores pró-inflamatórios sistemicamente (Costa *et al.* 2023). Por se tratar de uma doença auto-imune, citocinas como a IL-6 e TNF- $\alpha$  podem aumentar ainda mais a resistência insulínica, piorando o controle hiperglicêmico e potencializando a doença (Costa *et al.* 2023). Estudos em animais, demonstraram que em ratos com PA, há maior concentração de hemoglobina glicosilada que em animais diabéticos sem PA (Cintra *et al.* 2014). Além disso, estudos relacionando a doença periodontal com a diabetes, constataram que após o tratamento da doença periodontal, há melhora significativa da condição hiperglicêmica. Inclusive, há atualmente estratégias de promoção de saúde que visam uma atenção integrada a pacientes diabéticos visando a manutenção da saúde periodontal para que haja maior controle de doenças autoimunes (Herrera *et al.* 2023).

Diferente da doença periodontal, no entanto, ainda faltam estudos que ilustre a magnitude que a infecção endodôntica pode afetar a saúde sistêmica. Uma das formas de fazer esta avaliação é realizando estudos em animais. A vantagem destes estudos é que, diferente de um estudo em humanos, é possível isolar e deixar como única variável entre os espécimes a presença ou ausência de periodontite apical. Diante do exposto, o objetivo deste estudo é quantificar IL-6 e TNF- $\alpha$  no sangue, fígado e rins de ratos portadores de PA.

## **PROPOSIÇÃO**

O objetivo deste estudo foi avaliar o impacto da PA na saúde sistêmica de ratos Wistar por meio da quantificação das citocinas pró-inflamatórias TNF-  $\alpha$  e IL-6 no sangue, fígado e rim.

# Capítulo 1 – Artigo que será submetido a Archives of Oral Biology

**Apical periodontitis and diabetes increase inflammatory mediators in plasm,  
hepatic and renal tissues**

Marissa Oliveira Silva<sup>1</sup>, DDS, Luciano Tavares Angelo Cintra<sup>2</sup>, PhD, Mariane Maffei Azuma<sup>2</sup>, PhD, Valéria Marçal Felix de Lima<sup>2</sup>, PhD, Renata Oliveira Samuel<sup>1</sup>, PhD

<sup>1</sup>Department of Clinical Dentistry, Dental School, UNIUBE – Universidade de Uberaba, Uberaba, MG, Brazil

<sup>2</sup>Department of Endodontics, São Paulo State University (Unesp), School of Dentistry, Araçatuba, SP, Brazil.

### **Corresponding Author**

Dra. Renata Oliveira Samuel Department of Clinical Dentistry, Dental School, UNIUBE- Universidade de Uberaba, R: Nene Sabino, 1801

Uberaba – Minas Gerais, Brazil Tel: (0055) 34 9 98007096



## ABSTRACT

The aim of this study was to evaluate the influence of diabetes and/or apical periodontitis (AP) in TNF- $\alpha$  and IL-6 levels in the hematologic, hepatic and renal tissues of Wistar rats. Forty male rats were divided into four groups: normoglycemic rats (N), normoglycemic rats with AP (N-AP), rats with experimental diabetes (ED), rats with experimental diabetes and apical periodontitis (ED-AP). Diabetes was induced by injection of streptozotocin. Glycemic control was performed to confirm the development of the disease at the sixth and last day of the experimental period. The endodontic infection was induced by exposure of the upper right first molar to the oral environment. After 30 days, fragments of kidney and liver were obtained, as well as venous blood to quantify TNF- $\alpha$  and IL-6 levels by ELISA capture technique. The values obtained were tabulated and analyzed statistically by means of two way analysis of variance tests (ANOVA) and Tukey test ( $p < 0.05$ ). The results showed increased TNF- $\alpha$  serum levels in the group N-AP when compared to the group N ( $p < 0.05$ ). Moreover, AP potencialized IL-6 levels in rat's liver in the group ED-AP when compared to the group N-AP ( $p < 0.05$ ). In diabetic rats, AP did not alter the levels of TNF- $\alpha$  and IL-6 in the plasm, renal and hepatic tissues ( $p > 0.05$ ). Furthermore, ED increased the TNF- $\alpha$  and IL-6 levels in plasm and renal tissue when compared with N rats ( $p < 0.05$ ). It may be concluded that AP may promote inflammatory systemic alterations as the increase of TNF- $\alpha$  serum levels and the pontencialize the IL-6 production in hepatic tissues of diabetic rats. In addition, the presence of diabetes may increase the levels of IL-6 and TNF- $\alpha$  in the plasm and renal tissue. Clinical significance AP is capable of promote systemic inflammatory alterations alone or when is associated with diabetes.

**Key words:** apical periodontitis, diabetes, IL-6, TNF- $\alpha$

## INTRODUCTION

Apical periodontitis (AP) is an infectious lesion characterized by inflammatory bone destruction that is mediated by various cytokines secreted from immunocompetent cells that have infiltrated the periapical tissues in response to intracanal bacterial infection (Kawashima *et al.* 1996). TNF- $\alpha$  and IL-6 are proinflammatory cytokines that play an important role in initiating and coordinating the cellular events that make up the immune system's response to infection (Kabashima *et al.* 2002). Previous studies have related the role of these cytokines in the AP pathogenesis (Gazivoda *et al.* 2009; Martinho *et al.* 2012; Azuma *et al.* 2014), specially related with their capacity to activate osteoclastic bone resorption (Kawashima *et al.* 2007; Silva *et al.* 2007, Torres-Monjarás *et al.* 2023).

In addition, TNF- $\alpha$  and IL-6 plays an active role in the diabetes pathogenesis (Sun *et al.* 2010; Ahad *et al.* 2014; Volpe *et al.* 2014; Turner *et al.* 2014, Hosseine *et al.* 2023), specially exacerbating the consequences of this disease, as diabetic nephropathy (Navarro-Gonzalez *et al.* 2008; Ahad *et al.* 2014, Mansoor *et al.* 2022) and the development of oral complications (Sun *et al.* 2010; Marigo *et al.* 2011; Zhao *et al.* 2011; Cintra *et al.* 2014, Martinho *et al.* 2021). Other studies have shown that AP associated with periodontal disease altered systemic conditions in diabetic rats, represented by an increase of triglyceride levels (Cintra *et al.* 2013), glycaemia (Cintra *et al.* 2014a), inflammatory cells (Cintra *et al.* 2014b) and IL-17 serum levels (Cintra *et al.* 2014c). Nevertheless, the literature needs more information about the relationship between AP and systemic health. Thus, the aim of this study was to evaluate the influence of diabetes and/or AP in TNF- $\alpha$  and IL-6 levels in the hematologic, hepatic and renal tissues of Wistar rats.

## METHODS

### Experimental design

Forty three-month-old male Wistar rats, each weighting 250-280g, were used in the study. The rats were divided into four groups: N- normoglycemic rats; N-AP- normoglycemic rats with apical periodontitis; ED- experimental diabetes; ED-AP- experimental diabetes with apical periodontitis, which were housed in mini-isolator for rats (Alesco, São Paulo, Brazil) in temperature-controlled rooms ( $25 \pm 1^\circ\text{C}$ ) and were given ad libitum access to water and food. The experimental protocol was approved by and conducted in accordance with guidelines of the institutional ethical committee (CEEA 023/2017/ Uniube).

The rats were fasted overnight (14-16h), and tail-tip blood was used to measure the fasting blood glucose monitoring system (Accu-Check® Performa; Roche Diagnostics Corporation, IN, USA). Subsequently, the rats were intramuscularly anesthetized with ketamine (87 mg/kg; Francotar; Virbac do Brasil Ind. Com. Lta., SP, Brazil), and xylazine (13 mg/kg; Rompum; Bayer S.A., São Paulo, Brazil). The rats were randomly assigned into groups and were endovenously injected in the penile vein with either citrate buffer solution (0.01 M, pH 4.5) (groups N and N-AP; n=20) or with streptozotocin (Sigma- Aldrich Corp., MO, USA) (groups ED and ED-AP; n=20). Streptozotocin was dissolved in citrate buffer solution at 35 mg/kg body weight for experimental induction of diabetes (Cintra *et al.*, 2013; Cintra *et al.*, 2014).

Six days after diabetics induced, blood samples were collected from each rat to determine their blood glucose levels. The rats with blood glucose levels of more than 200 mg/dL were used in this study (Garber *et al.* 2009).

### Induction of endodontic infection

After confirmation of hyperglycemia, animals were anesthetized for the induction of AP with ketamine (87 mg/kg; Francotar; Virbac do Brasil Ind. Com. Lta., Brazil), and xylazine (13 mg/kg; Rompum; Bayer S.A., São Paulo, Brazil) intramuscularly.

For the development of AP, the pulps of the right upper first molars were exposed on the mesial surface using surgical round burs (Broca Ln Long Neck- Maillefer; Dentisply Ind. Com. Ltda, RJ, Brazil) (groups N-AP and ED-AP; n=20) (Garber *et al.* 2009).

#### Assessment of TNF- $\alpha$ and IL-6 in hematologic, hepatic and renal tissues

After 30 days, the rats were killed with an overdose of the anesthetic solution. The left kidneys of each rat and a fragment of the liver were collected and were immediately preserved in liquid nitrogen to avoid cytokine degradation. Fragments of kidney and liver were obtained to quantify TNF- $\alpha$  and IL-6 by ELISA capture technique. For this, 0,2g of tissues and 800  $\mu$ l of sterile PBS, pH 7.0, were kept in ice and ground in a tissue homogenizer (Ultraturrax T8; IKA, Germany) for approximately 5 min. The resulting homogenate was centrifuged at 10,000 x g for 15 min at 4°C and the supernatant was immediately stored at -80°C (Revco, USA).

The blood were collected by cardiac puncture and were centrifuged immediately after collection at 1,800xg for 15 min at 4 °C to obtain plasma. The plasma (200  $\mu$ L), which was cooled immediately to -80 °C, was used to determine the plasma TNF- $\alpha$  and IL-6 levels. The capture ELISA was performed using extract of kidney and liver and blood plasma with rat anti-mouse monoclonal antibody produced in cat and biotin rat anti-mouse monoclonal antibody produced in cat (BD Pharmingen™, CA, USA). Plates with 96 wells (Costar™, Washington DC, USA) were sensitized with 1 $\mu$ g/ml and 4 $\mu$ g/ml for TNF- $\alpha$  and IL-6, respectively. The detection antibody were with the 1 $\mu$ g/ml and 4 $\mu$ g/ml concentrations for TNF- $\alpha$  and IL-6, respectively. Rat recombinant of TNF- $\alpha$  and IL-6 (BD Pharmingen™, CA, USA) were used to generate a standard curves. The test was developed with 3,3',5'-tetramethylbenzidine-TMB (BD Pharmingen™, CA, USA) in accordance with manufacture's instructions, and plates were read by the microplate EZ read 400 (Biochrom, MA, USA) with 450nm filter.

## **STATISTICAL ANALYSIS**

The total assessed values were tabulated for each experimental group. Two-way analysis of variance (ANOVA) and the Tukey's test were used for statistical analysis, and a significance level of 5% ( $p < 0.05$ ) was used to compare the mean values.

## RESULTS

The results may be seen in table 1 and figures 1 and 2. It may be seen that the normoglycemic rats with AP (N-AP) showed higher TNF- $\alpha$  levels in the hematologic tissue when compared to normoglycemic rats without AP (N) ( $p < 0.05$ ). There is no statistical difference in the TNF- $\alpha$  levels between diabetic rats without apical periodontitis (ED) and diabetic rats with apical periodontitis (ED-AP) ( $p > 0.05$ ). The AP did not alter the TNF- $\alpha$  levels in renal tissues ( $p > 0.05$ ) of diabetic rats as much as normoglycemic rats ( $p > 0.05$ ).

On the other hand, the presence of diabetes and/or AP did not alter the TNF- $\alpha$  levels in hepatic tissue ( $p > 0.05$ ). However, it may be observe a significance increase in the TNF- $\alpha$  levels in hematologic and renal tissues of diabetic rats (ED and ED-AP) when compared to normoglycemic rats (N and N-AP) ( $p < 0.05$ ).

Regarding the IL-6 levels, it may be observe a significance increase in the IL-6 levels in hematologic, hepatic and renal tissues of diabetic rats (ED and ED-AP) when compared to normoglycemic rats (N and N-AP) ( $p < 0.05$ ). The AP alone did not alter the IL-6 levels in normoglycemic (N and N-AP) nor in diabetic rats (ED and ED+AP) ( $p > 0.05$ ).

## DISCUSSION

The rats used in this study had uniform body weights and were normoglycemic. Diabetes mellitus was induced by injecting the rats with streptozotocin. The glucose levels were found to be approximately six fold higher than those observed in normoglycemic rats. Diabetic rats showed intense thirst, polyuria, and apathy. The overall metabolism of rats with streptozotocin-induced diabetes is very similar to the metabolism of human diabetic patients (Kohsaka *et al.*, 1996). The blood glucose levels were higher in the rats of the diabetic model group than in those of the normal control group, indicating that hyperglycemia persisted in the diabetic rats.

A model of oral infection were used as described previously (Garber *et al.* 2009; Cintra *et al.* 2013; Cintra *et al.* 2014 abc; Samuel *et al.* 2019). A previous study reported maximal active lesion expansion and bone destruction between days 7 and 15 after pulp exposure in a rat model system in which periapical lesions had been induced (Kohsaka *et al.*, 1996).

The data obtained and the statistical analysis showed that the presence of diabetes and/or endodontic infection did not alter TNF- $\alpha$  and IL-6 levels in hepatic tissues ( $p>0.05$ ) when compared to other bodies and more studies should be performed for explain these results. In the renal tissues, we may observe an increase of TNF- $\alpha$  and IL-6 levels in diabetic rats (ED and ED-AP) when compared with nomorglycemic rats (N and N-AP). It may occurs because the kidney is the major organ to have damage in diabetic conditions, represented by diabetic nephropathy. Diabetic nephropathy is a serious renal lesion, characterized by renal dysfunction, fibrosis and glomerulosclerosis (Heerspink & Zeeuw. 2011; Franceschini *et al.* 2012; Meguro *et al.* 2012). Although the diabetic nephropathy has many factors, dyslipidemia and lipotoxicity further play an important role in the development of pathological process (Athyros *et al.* 2010; Rutledge *et al.* 2010; Kim *et al.* 2013). The dyslipidemia associated with diabetes leads to excessive accumulation of lipids in the kidneys, which causes serious kidney damage as well as increased insulin resistance, oxidative stress and inflammation (Wahba & Mak *et al.* 2007; Murea *et al.* 2010; Das *et al.* 2019). The inflammatory response has also been considered a major mechanism by which lipotoxicity causes diabetic oxidative stress disorder and structural abnormalities in the kidney, through the release of various inflammatory factors (Lin *et al.* 2008; Navarro-

Gonzalez & Mora-Fernandez. 2008; Rivero *et al.* 2009). On the other hand, AP did not alter the TNF- $\alpha$  and IL-6 levels in renal tissue ( $p > 0.05$ ), both in diabetic rats and normoglycemic rats, neither the IL-6 levels in plasma. However, there are studies in the literature that showed that the periodontal disease may increase the TNF- $\alpha$  and IL-6 serum levels in normoglycemic patients (Khanna & Mali 2010; George *et al.* 2013; Danielsen *et al.* 2023) and in diabetic patients (Sun *et al.* 2010; Sun *et al.* 2011; Marigo *et al.* 2011; Zhao. 2011). It is known that the pathogenesis of periodontal disease is similar to the AP pathogenesis, represented by the organism response against aggressor agent, resulting in the release of inflammatory mediators and consequent bone resorption (Silva *et al.* 2007). It shows us that more researches need to be conducted regarding the influence of apical periodontitis in tissues, during the presence or absence of systemic diseases.

In addition, this study showed that the TNF- $\alpha$  and IL-6 serum levels increased in diabetic rats (ED and ED-AP) when compared to normoglycemic rats (N and N-AP) ( $p < 0.05$ ), which agrees with other studies in the literature, where it was observed an increase in TNF- $\alpha$  and IL-6 serum levels in the presence of diabetes (Sun *et al.* 2010; Turner *et al.* 2014; Volpe *et al.* 2014; Danielsen *et al.*, 2023). This increase interfered negatively in diabetics glycemic control (Sun *et al.* 2010; Sun *et al.* 2011; Marigo *et al.* 2011; Danielsen *et al.*, 2023). Furthermore, normoglycemic rats with apical periodontitis (N-AP) showed higher TNF- $\alpha$  serum levels as compared with normoglycemic rats ( $p < 0.05$ ), which is in agreement with other study performed in normoglycemic with apical periodontitis (Astolpho *et al.* 2013, Giorgiou *et al.* 2023), as well as in patients with periodontal disease (Khanna & Mali. 2010). There was no statistical difference between TNF- $\alpha$  serum levels in diabetic rats (ED) compared to diabetic rats with apical periodontitis (ED+AP) ( $p > 0.05$ ). It may be explained because the increase of TNF- $\alpha$  serum levels was insignificant when compared to the large increase in rats with diabetes. It may be concluded that the presence of diabetes may increase the levels of IL-6 and TNF- $\alpha$  in hematologic and renal tissue.

The presence of apical periodontitis may promote systemic alterations as the increase of TNF- $\alpha$  serum levels. In addition, the presence of apical periodontitis may potencialize the IL-6 production in hepatic tissues of diabetic rats. These results show the importance of the dental health for the body hemostasis.



## **ACKNOWLEDGMENTS**

This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – Finance Code 001. The authors deny any conflicts of interest related to this study.

## REFERENCE

1. A K DAS, S KALRA, M TIWASKAR, S BAJAJ, K SESHADRI, S CHOWDHURY, et al. Expert Group Consensus Opinion: Role of Anti-inflammatory Agents in the Management of Type-2 Diabetes (T2D) **J Assoc Physicians India**. 2019. Dec;67(12):65-74.
2. AHAD A, GANAI AA, MUJEEB M, SIDDIQUI WA. Chrysin, an anti-inflammatory molecule, abrogates renal dysfunction in type 2 diabetic rats. **Toxicol Appl Pharmacol**. 2014 Aug 15;279(1):1-7.
3. ASTOLPHI RD, CURBETE MM, COLOMBO NH, SHIRAKASHI DJ, CHIBA FY, PRIETO AK, CINTRA LT, BOMFIM SR, ERVOLINO E, SUMIDA DH. Periapical lesions decrease insulin signal and cause insulin resistance. **J Endod**. 2013;39(5):648-52.
4. ATHYROS VG, MITSIOU EK, TZIOMALOS K, KARAGIANNIS A, MIKHAILIDIS DP. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. **Expert Opin Pharmacother**. 2010;11(5): 723-30.
5. AZUMA MM, GOMES-FILHO JE, PRIETO AK, SAMUEL RO, LIMA VM, SUMIDA DH et al. Diabetes increases interleukin-17 levels in periapical, hepatic, and renal tissues in rats. **Arch Oral Biol**. 2017 Nov;83:230-5.
6. AZUMA MM, SAMUEL RO, GOMES-FILHO JE, DEZAN-JUNIOR E, CINTRA LT. The role of IL-6 on apical periodontitis: a systematic review. **Int Endod J**. 2014 Jul;47(7):615-21. doi: 10.1111/iej.12196. Epub 2013 Nov 14.
7. BILLINGS F. Mouth infection as a source of systemic disease. **J Am Med Assoc**. 1914;63:2024.
8. CINTRA LT, FACUNDO AC, PRIETO AK, SUMIDA DH, NARCISO LG, BOMFIM SR, OLIVEIRA E SILVA C, DEZAN-JÚNIOR E, GOMES-FILHO JE. Blood profile and histology in oral infections associated with diabetes. **J Endod**. 2014 Aug;40(8):1139-44. a
9. CINTRA LT, FACUNDO AC, AZUMA MM, SUMIDA DH, ASTOLPHI RD, BOMFIM SR, NARCISO LG, GOMES-FILHO JE. Pulpal and periodontal diseases increase triglyceride levels in diabetic rats. **Clin Oral Investig**. 2013; 17(6):15959.
10. CINTRA LT, SAMUEL RO, AZUMA MM, RIBEIRO CP, NARCISO LG, LIMA VM, SUMIDA DH, COCLETE GA, DEZAN-JÚNIOR E, GOMES-FILHO JE. Apical periodontitis and periodontal disease increase serum IL-17 levels in normoglycemic and diabetic rats. **Clin Oral Investig**. 2014 Dec;18(9):2123-8. B
11. CINTRA LT, SAMUEL RO, FACUNDO AC, PRIETO AK, SUMIDA DH, BOMFIM SR, SOUZA JC, DEZAN-JÚNIOR E, GOMES-FILHO JE. Relationships between oral infections and blood glucose concentrations or HbA1c levels in normal and diabetic rats. **J Endod**. 2014; 47:228-37. C

12. CLARKE NG, HIRSCH RS. Personal risk factors for generalized periodontitis. **J Clin Periodontol.** 1995;22(2):136-45. Review.
13. CLAUSE BT. The Wistar Rat as a right choice: establishing mammalian standards and the ideal of a standardized mammal. **J Hist Biol.** 1993 Summer;26(2):329-49.
14. COSTA R, RÍOS-CARRASCO B, MONTEIRO L, LÓPEZ-JARANA P, CARNEIRO F, RELVAS M. Association between Type 1 Diabetes Mellitus and Periodontal Diseases. **J Clin Med.** 2023 Feb 1;12(3):1147. doi: 10.3390/jcm12031147.
15. DANIELSEN AK, DAMGAARD C, MASSARENTI L, ØSTRUP P, RIIS P, HOLMSTRUP P, NIELSEN CH. B-cell cytokine responses to *Porphyromonas gingivalis* in patients with periodontitis and healthy controls. **J Periodontol.** 2023 Jan 30. doi: 10.1002/JPER.22-0438.
16. EASLICK K. An evaluation of the effect of dental foci of infection on health. **J Am Dental Assoc.** 1951;42: 615-97.
17. FOUAD A. Diabetes mellitus as a modulating factor of endodontic infections. **J Dent Educ,** v. 67, p. 459-466, 2003
18. FRANCESCHINI N, SHARA NM, WANG H, VORUGANTI VS, LASTON S. The association of genetic variants of type 2 diabetes with kidney function. **Kidney Int.** 2012; 82: 220–225
19. GARBER, S.E.; SHABAHANG, S.; ESCHER, A.P.; TORABINEJAD, M. The effect of hyperglycemia on pulpal healing in rats. *Journal of Endodontics*, v. 35, n. 1, p. 60-62, 2009.
20. GAZIVODA D, DZOPALIC T, BOZIE B, TATOMIROVIC Z, BRKIC Z, COLIC M. Production of proinflammatory and immunoregulatory cytokines by inflammatory cells from periapical lesions in culture. **J Oral Pathol Med.** 2009 Aug;38(7):605-11.
21. GENCO RJ, LOE H. The role of systemic conditions and disorders in periodontal disease. **Periodontol** 2000. 1993;2:98-116.
22. GEORGE AK, JANAM P. The short-term effects of non-surgical periodontal therapy on the circulating levels of interleukin-6 and C-reactive protein in patients with chronic periodontitis. **J Indian Soc Periodontol.** 2013 Jan;17(1):36-41.
23. GEORGIU AC, WAAL SV, BUIJS MJ, CRIELAARD W, ZAURA E, BRANDT BW. Host microbiome interactions in apical periodontitis: the endodontic microbiome in relation to circulatory immunologic markers. **Int Endod J.** 2023 Mar 14. doi: 10.1111/iej.13912.
24. GROSS, J.L.; SILVEIRO, S.P.; CAMARGO, J.L.; REICHEL, A.L.; AZEVEDO, M.J. Diabetes Mellito: Diagnóstico, Classificação e Avaliação do Controle Glicêmico. **Arq Bras Endocrinol Metab,** v. 46, n. 1, 2002.

25. HEERSPINK HJ, ZEEUW D. The kidney in type 2 diabetes therapy. **Rev Diabet Stud.** 2011;8(3):392-02.
26. HERRERA D, SANZ M, SHAPIRA L, BROTONS C, CHAPPLE I, FRESE T, et al. Vinker S. Association between periodontal diseases and cardiovascular diseases, diabetes and respiratory diseases: Consensus report of the Joint Workshop by the European Federation of Periodontology (EFP) and the European arm of the World Organization of Family Doctors (WONCA Europe). **J Clin Periodontol.** 2023 Mar 19. doi: 10.1111/jcpe.13807.
27. HOSSEINI MOKHTARI Z, SALEHI ABARGOUEI A, MISHRA GD, AMANI R. Maternal circulating leptin, tumor necrosis factor-alpha, and interleukine-6 in association with gestational diabetes mellitus: a systematic review and meta-analysis. **Gynecol Endocrinol.** 2023 Dec;39(1):2183049. doi: 10.1080/09513590.2023.2183049.
28. HUNTER W. Oral sepsis as a cause of disease. **British Medical J.** 1900;2:215–6.
29. KABASHIMA H, NAGATA K, MAEDA K, IJIMA T. Involvement of substance P, mast cells, TNF-alpha and ICAM-1 in the infiltration of inflammatory cells in human periapical granulomas. **J Oral Pathol Med.** 2002 Mar;31(3):175-80.
30. KAWASHIMA N, OKIJI T, KOSAKA T, SUDA H. Kinetics of macrophages and lymphoid cells during the development of experimentally induced periapical lesions in rat molars: a quantitative immunohistochemical study. **J Endod.** 1996; 22(6):311-6.
31. KAWASHIMA N, SUZUKI N, YANG G, OHI C, Okuhara S, NAKANO-KAWAWANISHI H, SUDA H. Kinetics of RANKL, RANK and OPG expression in experimentally induced rat periapical lesions. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod.** 2007 May;103(5):707-11.
32. KHANNA S, MALI AM. Evaluation of tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) levels in plasma and their correlation with periodontal status in obese and non-obese subjects. **J Indian Soc Periodontol.** 2010 Oct;14(4):217-21
33. KIM MY, LIM JH, YOUN HH, HONG YA, YANG KS, et al. Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1alpha axis in db/db mice. **Diabetologia.** 2013; 56(1):204-17.
34. KOHSAKA T, KUMAZAWA M, YAMASAKI M, NAKAMURA H. Periapical lesions in rats with streptozotocin-induced diabetes. **J Endod** 1996. 22:418–21.
35. LIN J, GLYNN RJ, RIFAI N, MANSON JE, RIDEKER PM, NATHAN DM, SCHAUMBERG DA. Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial. **Diabetes Care.** 2008;31(12):2338-43.

36. MARÇAL JR, SAMUEL RO, FERNANDES D, de ARAUJO MS, NAPIMOGA MH, et al. T-helper cell type 17/regulatory T-cell immunoregulatory balance in human radicular cysts and periapical granulomas. **J Endod.** 2010;36(6):995-9.
37. MARIGO L, CERRENTO R, GIULIANI M, SOMMA F, LAJOLO C, CORDARO M. Diabetes mellitus: biochemical, histological and microbiological aspects in periodontal disease. **Eur Rev Med Pharmacol Sci.** 2011 Jul;15(7):751-8.
38. MARQUINI, M. A.; MARQUINI, M. A.; CRAVEIRO, M. A.; TOGNETTI, V. M. CORRELAÇÃO ENTRE PERIODONTITE APICAL E DIABETES MELLITUS: UMA REVISÃO DA LITERATURA. **Ensaio USF**, [S. l.], v. 4, n. 2, 2022. DOI: 10.24933/eusf.v4i2.175. Disponível: <https://ensaios.usf.edu.br/ensaios/article/view/175>. Acesso em: 24 mar. 2023.
39. MARTINHO FC, CHIESA WM, LEITE FR, CIRELLI JA, GOMES BP. Correlation between clinical/radiographic features and inflammatory cytokine networks produced by macrophages stimulated with endodontic content. **J Endod.** 2012 Jun;38(6):740-5.
40. MARTINHO FC, LEITE FRM, ARRUDA-VASCONCELOS R, LOUZADA LM, DARVEU RP, GOMES BPPA. Influence of Bacterial Profiles in Cytokine and Clinical Features of Endodontic Disease. **J Endod.** 2021 Aug;47(8):1265-1271. doi: 10.1016/j.joen.2021.04.026. Epub 2021 May 18.
41. Miller WD. The human mouth as a focus of infection. **Dental Cosmos.** 1891;33:689–706.
42. MILLS A. Oral sepsis in general practice. **Br Med J.** 1913;1(2737):1264–1267.
43. MUREA M, FREEDMAN BI, PARKS JS, ANTINOZZI PA, ELBEIN SC et al. Lipotoxicity in diabetic nephropathy: the potential role of fatty acid oxidation. **Clin J Am Soc Nephrol.** 2010;5(12): 2373-9.
44. NAVARRO-GONZÁLEZ JF<sup>1</sup>, MORA-FERNÁNDEZ C. The role of inflammatory cytokines in diabetic nephropathy. **J Am Soc Nephrol.** 2008 Mar;19(3):433-42.
45. OGLE OE. Odontogenic Infections. **Dent Clin North Am.** 2017;61(2):235-252. Review.
46. PRABHU A, MICHALOWICZ BS, MATHUR A. Detection of local and systemic cytokines in adult periodontitis. **J Periodontol.** 1996;67(5):515-22.
47. PRICE WA. Dental infections and related degenerative diseases. **J Am Med Assoc.** 1925;84:254.
48. RIVERO A, MORA C, MUROS M, GARCIA J, HERRERA H, NAVARRO-GONZÁLEZ JF. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. **Clin Sci (Lond).** 2009; 116(6):479-92.

- 49.ROSENOW EC. Elective localization of bacteria in the animal body. In: **Jordan EO**, Falk IS, eds. *The Newer Knowledge of Bacteriology and Immunology*. 1928;576–89.
- 50.RUTLEDGE JC, NG KF, AUNG HH, WILSON DW. Role of triglyceride-rich lipoproteins in diabetic nephropathy. **Nat Rev Nephrol**. 2010; 6(6):361-70.
- 51.SAMUEL RO, ERVOLINO E, AZEVEDO ÍO, AZUMA MM, FERREIRA GT, CINTRA LTA.Th1/Th2/Th17/Treg Balance in Apical Periodontitis of Normoglycemic and Diabetic Rats. **J Endod**. 2019 Aug;45(8):1009-1015. doi: 10.1016/j.joen.2019.05.003. Epub 2019 Jun 19.
- 52.SANZ M, CERIELLO A, BUYSSCHAERT M, CHAPPLE I et al. Scientific evidence on the links between periodontal diseases and diabetes: Consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International diabetes Federation and the European Federation of Periodontology. *Diabetes Res Clin Pract*. 2018;137:231-241.
- 53.SILVA TA, GARLET GP, FUKADA SY, SILVA JS, CUNHA FQ Chemokines in oral inflammatory diseases: apical periodontitis and periodontal disease. **J D Res**. 2007; (86): 306-19.
- 54.SUN WL, CHEN LL, ZHANG SZ, REN YZ, QIN GM. Changes of adiponectin and inflammatory cytokines after periodontal intervention in type 2 diabetes patients with periodontitis. **Arch Oral Biol**. 2010 Dec;55(12):970-4.
- 55.SUN WL, CHENA LL, ZHANG SZ, WU YM, REN YZ, QIN GM. Inflammatory cytokines, adiponectin, insulin resistance and metabolic control after periodontal intervention in patients with type 2 diabetes and chronic periodontitis. **Intern Med**. 2011;50(15):1569-74. Epub 2011 Aug 1.
- 56.TORRES-MONJARÁS AP, SÁNCHEZ-GUTIÉRREZ R, HERNÁNDEZ-CASTRO B, GONZÁLEZ-BARANDA L, et al. Bacteria associated with apical periodontitis promotes in vitro the differentiation of macrophages to osteoclasts. **Clin Oral Investig**. 2023 Feb 17. doi: 10.1007/s00784-023-04920-8. Online ahead of print.
- 57.TURNER D, LUZIO S, KILDUFF LP, GRAY BJ, DUNSEATH G, BAIN SC, CAMPBELL MD, WEST DJ, BRACKEN RM. Reductions in resistance exercise-induced hyperglycaemic episodes are associated with circulating interleukin-6 in Type 1 diabetes. **Diabet Med**. 2014 Aug;31(8):1009-13.
- 58.VAIZEY JM, CLARK-KENNEDY AE. **Dental Sepsis: Anaemia, Dyspepsia, and Rheumatism**. **Br Med J**. 1939;1(4094):1269-73.
- 59.VOLPE CM, ABREU LF, GOMES PS, GONZAGA RM, VELOSO CA, NOGUEIRA-MACHADO JA. The production of nitric oxide, IL-6, and TNF-alpha in palmitate-stimulated PBMNCs is enhanced through hyperglycemia in diabetes. **Oxid Med Cell Longev**. 2014; 2014

60.WAHBA IM, MAK RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. **Clin J Am Soc Nephrol.** 2007;2(3):550-62.

61.WAI T, ITOH H, ATSUMI H. Factors Associated with the Decline of Kidney Function Differ among eGFR Strata in Subjects with Type 2 Diabetes Mellitus. **Int J Endocrinol.** 2012; 2012.


62.ZHAO L, ZHOU Y, XU Y, SUN Y, Li L, CHEN W. Effect of non-surgical periodontal therapy on the levels of Th17/Th1/Th2 cytokines and their transcription factors in Chinese chronic periodontitis patients. **J Clin Periodontol.** 2011 Jun;38(6):509-16.

**Table 1.** TNF- $\alpha$  and IL-6 levels in hepatic and renal tissues and plasm. Different letters indicate significant statistical differences in the columns (p<0.05).


Groups	TNF- $\alpha$ levels (pg/mL)			IL-6 levels (pg/mL)		
	Hepatic tissue	Renal tissue	Plasm	Hepatic tissue	Renal tissue	Plasm
N	1357,832 $\pm$ 154,269 <sup>a</sup>	1479,811 $\pm$ 209,636 <sup>a</sup>	44,99 $\pm$ 26,085 <sup>a</sup>	62234,7 $\pm$ 7998 <sup>a</sup>	34113,5 $\pm$ 7479,7 <sup>a</sup>	4213,1 $\pm$ 2703,7 <sup>a</sup>
N-AP	1254,082 $\pm$ 293,200 <sup>a</sup>	1407,812 $\pm$ 465,573 <sup>a</sup>	233,944 $\pm$ 20,078 <sup>b</sup>	55880,1 $\pm$ 16870,7 <sup>a</sup>	41600,6 $\pm$ 9535,4 <sup>a</sup>	3153,5 $\pm$ 1475,2 <sup>a</sup>
ED	1450,227 $\pm$ 152,296 <sup>a</sup>	1869,369 $\pm$ 439,230 <sup>b</sup>	736,28 $\pm$ 249,389 <sup>c</sup>	72823,5 $\pm$ 7375,1 <sup>b</sup>	57181,3 $\pm$ 8369,375 <sup>b</sup>	22827,1 $\pm$ 4306,8 <sup>b</sup>
ED-AP	1330,693 $\pm$ 254,121 <sup>a</sup>	2042,227 $\pm$ 246,540 <sup>b</sup>	814,458 $\pm$ 171,325 <sup>c</sup>	73814,1 $\pm$ 6784,6 <sup>bc</sup>	58203,3 $\pm$ 10212 <sup>b</sup>	24237,8 $\pm$ 3403,3 <sup>b</sup>



**Figure 1.** TNF- $\alpha$  levels in hepatic and renal tissues and plasm.



**Figure 2.** IL-6 levels in hepatic and renal tissues and plas



## ANEXO

### ANEXO 1- Normas da revista Archives of Oral Biology



## ARCHIVES OF ORAL BIOLOGY

A Multidisciplinary Journal of Oral & Craniofacial Sciences

### AUTHOR INFORMATION PACK

#### TABLE OF CONTENTS

• Description	p.1
• Audience	p.1
• Impact Factor	p.1
• Abstracting and Indexing	p.2
• Editorial Board	p.3
• Guide for Authors	p.4



#### DESCRIPTION

*Archives of Oral Biology* is an international journal which aims to publish papers of the highest scientific quality in the oral and craniofacial sciences including:

Developmental biology Cell and molecular biology Molecular genetics Immunology Pathogenesis Microbiology Biology of dental caries and periodontal disease Forensic dentistry Neuroscience Salivary biology Mastication and swallowing Comparative anatomy Paeleodontology

*Archives of Oral Biology* will also publish expert reviews and articles concerned with advancement in relevant methodologies. The journal will only consider clinical papers where they make a significant contribution to the understanding of a disease process.

What is below is currently what is written on the Journal's Aims and Scopes page please remove Journal Metrics from it which I will add in bold and italicize as well.

*Archives of Oral Biology* will also publish expert reviews and articles concerned with advancement in relevant methodologies. The journal will only consider clinical papers where they make a significant contribution to the understanding of a disease process.

#### AUDIENCE

Oral biologists, physiologists, anatomists, pathologists.

#### IMPACT FACTOR

---

## ABSTRACTING AND INDEXING

---

Elsevier BIOBASE  
Nutrition Research Newsletter  
Nutrition Abstracts and Reviews Series  
PharmacoEconomics and Outcomes News  
Pig News and Information  
Reactions Weekly  
Review of Medical and Veterinary Entomology  
Science Citation Index  
SIIC Data Bases  
Soils and Fertilizers  
Sugar Industry Abstracts  
Tropical Diseases Bulletin  
Veterinary Bulletin  
Vitis Viticulture and Enology Abstracts  
Biological Abstracts  
Animal Breeding Abstracts  
BIOSIS Previews  
Current Awareness in Biological Sciences  
Abstracts in Anthropology  
Abstracts on Hygiene and Communicable Diseases  
Dairy Science Abstracts  
GeoRef  
Index Veterinarius  
Inpharma Weekly  
Medical and Surgical Dermatology  
Abstracts of Mycology  
AgBiotech News and Information  
Maize Abstracts Online  
Postharvest News and Information  
Review of Agricultural Entomology  
Small Animals  
Soybean Abstracts (Online Edition)  
Speleological Abstracts  
Agris  
Aquatic Sciences and Fisheries Abstracts  
Arts and Humanities Citation Index  
CABI Information  
Cancerlit  
Gale Database of Publications & Broadcast Media  
Global Health  
Inside Conferences  
ISI Science Citation Index  
Pascal Francis  
RTECS (Registry of Toxic Effects of Chemical Substances)  
Web of Science  
SPORTDiscus  
TOXFILE  
UnCover  
Zoological Record  
BIOSIS Toxicology  
CSA Life Sciences Abstracts  
Research Alert  
BIOSIS Citation Index  
Elsevier BIOBASE  
Chemical Abstracts  
Current Contents - Life Sciences  
Current Contents  
Current Contents  
Current Contents  
PubMed/Medline  
ARCHOR INFORMATION PACK 10 Mar 2023

[www.elsevier.com/locate/archoralbio](http://www.elsevier.com/locate/archoralbio)

2

---

## **EDITORIAL BOARD**

### ***Editors-in-Chief***

**P.M. Castelo**, Federal University of Sao Paulo, Institute of Environmental, Chemical and Pharmaceutical Sciences, Diadema, Brazil

**F. T. Lundy**, Queen's University Belfast, BT7 1NN, Belfast, United Kingdom

### ***Associate Editors***

**G.N. Belibasakis**, Karolinska Institute, Stockholm, Sweden

**D. Grenier**, Laval University, Québec, Quebec, Canada

**M.Q. Wang**, Air Force Medical University, Xian, China

### ***Editorial Board***

**O. Andrukhov**, Wien, Austria

**V. Arana-Chavez**, SAO PAULO, Brazil

**Z. Bian**, Wuhan, China

**G. H. Carpenter**, London, United Kingdom

**J-h Chen**, Xian, China

**K. Cogo-Müller**, SAO PAULO, Brazil

**X. Duan**, Xian, China

**M.B.D. Gavião**, CAMPINAS, Brazil

**H. van der Glas**, Utrecht, Netherlands

**S. Herring**, Seattle, United States of America

**Y. Jin**, Xian, China

**C. P. McArthur**, Kansas City, United States of America

**M. Mei**, Dunedin, New Zealand

**G. Murray**, Sydney, Australia

**J. Y. Ro**, Baltimore, United States of America

**C. Robinson**, Leeds, United Kingdom

**L. P. Samaranayake**, Hong Kong, Hong Kong

**B.J. Sessle**, Toronto, Canada

**P.T. Sharpe**, London, United Kingdom

**A.J. Smith**, Birmingham, United Kingdom

**D Steinberg**, Jerusalem, Israel

**H. Suda**, Bunkyo-Ku, Japan

**K. Tanne**, Higashihiroshima, Japan

**L. Walsh**, Brisbane, Australia

### ***Editor-In-Chief Emeritus***

**S.W. Cadden**, Dundee, United Kingdom

**B. Proctor**, London, United Kingdom

---

## GUIDE FOR AUTHORS

---

Editors-in-Chief:

**Professor S W Cadden, Dundee, Scotland**  
**Dr Fionnuala T. Lundy, Northern Ireland, UK**

Archives of Oral Biology is an international journal which aims to publish papers of the highest scientific quality reporting new knowledge from the orofacial region including:

- developmental biology
- cell and molecular biology
- molecular genetics
- immunology
- pathogenesis
- microbiology
- biology of dental caries and periodontal disease
- forensic dentistry
- neuroscience
- salivary biology
- mastication and swallowing
- comparative anatomy
- paeleodontology

Archives of Oral Biology will also publish expert reviews and articles concerned with advancement in relevant methodologies. The journal will consider clinical papers only where they make a significant contribution to the understanding of a disease process.

These guidelines generally follow the [Uniform Requirements for Manuscripts Submitted to Biomedical Journals](#)

### **Types of Contribution**

Original papers and review articles are welcomed. There will be no differentiation on the basis of length into full or short communications. Editorial commentaries will also be considered but only by invitation. All submissions will be refereed.

### **Page charges**

This journal has no page charges.

### **Submission checklist**

You should use this list to carry out a final check of your submission before you send it to the journal for review. Please check all relevant sections in this Guide for Authors for more details.

### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address

All necessary files have been uploaded:

#### *Manuscript:*

- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print

*Graphical Abstracts* (where applicable)

*Highlights* (mandatory)

*Supplemental files* (where applicable)

Further considerations

- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa

- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- Relevant declarations of interest have been made
- Declarations of authors' contributions have been made if there are four or more authors
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our [Support Center](#)

## **BEFORE YOU BEGIN**

### **Ethics in publishing**

Please see our information on [Ethics in publishing](#).

### **Studies in humans and animals**

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with [The Code of Ethics of the World Medical Association \(Declaration of Helsinki\)](#) for experiments involving humans. The manuscript should be in line with the [Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals](#) and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms [sex and gender](#) should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the [ARRIVE guidelines](#) and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, [EU Directive 2010/63/EU for animal experiments](#), or the National Research Council's [Guide for the Care and Use of Laboratory Animals](#) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

### **Declaration of interest**

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double anonymized) or the manuscript file (if single anonymized). If there are no interests to declare then please state this: 'Declarations of interest: none'. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. [More information](#).

### **Preprints**

Please note that [preprints](#) can be shared anywhere at any time, in line with Elsevier's [sharing policy](#). Sharing your preprints e.g. on a preprint server will not count as prior publication (see '[Multiple, redundant or concurrent publication](#)' for more information).

### **Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see '[Multiple, redundant or concurrent publication](#)' section of our ethics policy for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically, without the written consent of the copyright-holder. To verify originality, your article is likely to be checked by the originality detection service CrossCheck.

### **Use of inclusive language**

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health

---

condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. When coding terminology is used, we recommend to avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". We suggest using alternatives that are more appropriate and (self-) explanatory such as "primary", "secondary", "blocklist" and "allowlist". These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

### **Reporting sex- and gender-based analyses**

#### **Reporting guidance**

For research involving or pertaining to humans, animals or eukaryotic cells, investigators should integrate sex and gender-based analyses (SGBA) into their research design according to funder/sponsor requirements and best practices within a field. Authors should address the sex and/or gender dimensions of their research in their article. In cases where they cannot, they should discuss this as a limitation to their research's generalizability. Importantly, authors should explicitly state what definitions of sex and/or gender they are applying to enhance the precision, rigor and reproducibility of their research and to avoid ambiguity or conflation of terms and the constructs to which they refer (see Definitions section below). Authors can refer to the [Sex and Gender Equity in Research \(SAGER\) guidelines](#) and the [SAGER guidelines checklist](#). These offer systematic approaches to the use and editorial review of sex and gender information in study design, data analysis, outcome reporting and research interpretation - however, please note there is no single, universally agreed-upon set of guidelines for defining sex and gender.

#### **Definitions**

Sex generally refers to a set of biological attributes that are associated with physical and physiological features (e.g., chromosomal genotype, hormonal levels, internal and external anatomy). A binary sex categorization (male/female) is usually designated at birth ("sex assigned at birth"), most often based solely on the visible external anatomy of a newborn. Gender generally refers to socially constructed roles, behaviors, and identities of women, men and gender-diverse people that occur in a historical and cultural context and may vary across societies and over time. Gender influences how people view themselves and each other, how they behave and interact and how power is distributed in society. Sex and gender are often incorrectly portrayed as binary (female/male or woman/man) and unchanging whereas these constructs actually exist along a spectrum and include additional sex categorizations and gender identities such as people who are intersex/have differences of sex development (DSD) or identify as non-binary. Moreover, the terms "sex" and "gender" can be ambiguous—thus it is important for authors to define the manner in which they are used. In addition to this definition guidance and the SAGER guidelines, the [resources on this page](#) offer further insight around sex and gender in research studies.

#### **Author contributions**

All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted. If any individual contributed to a paper but did not meet all three of these criteria, they should be mentioned in an Acknowledgements section but must not be listed as an author (see Acknowledgements section below).

For transparency, and to show that they met the above criteria, authors should submit an author statement file outlining their individual contributions to the paper using the relevant CRediT roles: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review and editing. Authorship statements should be formatted with the names of authors first and CRediT role(s) following. More details and an example. [More details and an example](#).

#### **Changes to Authorship**

Authors are expected to consider carefully the list and order of authors before submitting their manuscript and to provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before

---

the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

#### *Article transfer service*

This journal uses the Elsevier Article Transfer Service to find the best home for your manuscript. This means that if an editor feels your manuscript is more suitable for an alternative journal, you might be asked to consider transferring the manuscript to such a journal. The recommendation might be provided by a Journal Editor, a dedicated [Scientific Managing Editor](#), a tool assisted recommendation, or a combination. If you agree, your manuscript will be transferred, though you will have the opportunity to make changes to the manuscript before the submission is complete. Please note that your manuscript will be independently reviewed by the new journal. [More information](#).

#### **Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see [more information](#) on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. [Permission](#) of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has [preprinted forms](#) for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete a 'License Agreement' ([more information](#)). Permitted third party reuse of gold open access articles is determined by the author's choice of [user license](#).

#### **Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

#### *Elsevier supports responsible sharing*

Find out how you can [share your research](#) published in Elsevier journals.

#### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement, it is recommended to state this.

#### **Open access**

Please visit our [Open Access page](#) for more information.

#### *Elsevier Researcher Academy*

[Researcher Academy](#) is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.



#### *Language (usage and editing services)*

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier's Author Services.

#### **Submission**

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

### **PREPARATION**

#### **Queries**

For questions about the editorial process (including the status of manuscripts under review) or for technical support on submissions, please visit our [Support Center](#).

#### **Peer review**

This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. [More information on types of peer review](#).

#### **REVISED SUBMISSIONS**

When submitting the revised manuscript, please make sure that you upload the final version of the paper with the changes highlighted. Please remove the old version(s) of the manuscript before submitting the revised version.

#### *Use of word processing software*

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To minimize unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

#### **Article structure**

##### *Manuscript Structure*

Follow this order when typing manuscripts: Title, Authors, Affiliations, Abstract, Keywords, Main text (Introduction, Materials & Methods, Results, Discussion for an original paper), Acknowledgments, Appendix, References, Tables and then Figure Captions. Do not import the Figures or Tables into your text. The corresponding author should be identified with an asterisk and footnote. All other footnotes (except for table footnotes) should be identified with superscript Arabic numbers.

##### *Introduction*

This should be a succinct statement of the problem investigated within the context of a brief review of the relevant literature. Literature directly relevant to any inferences or argument presented in the Discussion should in general be reserved for that section. The introduction may conclude with the reason for doing the work but should not state what was done nor the findings.

---

### *Materials and Methods*

Enough detail must be given here so that another worker can repeat the procedures exactly. Where the materials and methods were exactly as in a previous paper, it is not necessary to repeat all the details but sufficient information must be given for the reader to comprehend what was done without having to consult the earlier work.

Authors are requested to make plain that the conditions of animal and human experimentation are as outlined in the "Ethics" and "Studies on Animals" sections above

### *Results or Findings*

These should be given clearly and concisely. Care should be taken to avoid drawing inferences that belong to the Discussion. Data may be presented in various forms such as histograms or tables but, in view of pressure on space, presentation of the same data in more than one form is unacceptable.

### *Discussion*

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is occasionally appropriate. Avoid extensive citations and discussion of published literature.

### *Conclusions*

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion section.

### **Essential title page information**

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

As titles frequently stand alone in indexes, bibliographic journals etc., and indexing of papers is, to an increasing extent, becoming computerized from key words in the titles, it is important that titles should be as concise and informative as possible. Thus the animal species to which the observations refer should always be given and it is desirable to indicate the type of method on which the observations are based, e.g. chemical, bacteriological, electron-microscopic, histochemical, etc. A "running title" of not more than 40 letters and spaces must also be supplied. A keyword index must be supplied for each paper.

### **Highlights**

Highlights are mandatory for this journal as they help increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the examples here: [example Highlights](#).

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

### **Structured abstract**

The paper should be prefaced by an abstract aimed at giving the entire paper in miniature. Abstracts should be no longer than 250 words and should be structured as per the guidelines published in the Journal of the American Medical Association (JAMA 1995; 273: 27-34). In brief, the abstract should be

divided into the following sections: (1) Objective; (2) Design - if clinical, to include setting, selection of patients, details on the intervention, outcome measures, etc.; if laboratory research, to include details on methods; (3) Results; (4) Conclusions.

### **Keywords**

Immediately after the abstract, provide a maximum of 6 keywords, using British spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

### **Abbreviations**

As Archives of Oral Biology is a journal with a multidisciplinary readership, abbreviations, except those universally understood such as mm, g, min. u.v., w/v and those listed below, should be avoided if possible. Examples of abbreviations which may be used without definition are: ADP, AMP, ATP, DNA, RNA, EDTA, EMG, tris.

Other abbreviations used to improve legibility should be listed as a footnote on the title page as well as being defined in both the abstract and the main text on first usage. Chemical symbols may be used for elements, groups and simple compounds, but excessive use should be avoided. Abbreviations other than the above should not be used in titles and even these should be avoided if possible.

### **Statistical analysis**

Authors should ensure that the presentation and statistical testing of data are appropriate and should seek the advice of a statistician if necessary. A number of common errors should be avoided, e.g.: -

- Use of parametric tests when non-parametric tests are required
- Inconsistencies between summary statistics and statistical tests such as giving means and standard deviations for data which were analysed with non-parametric tests.
- Multiple comparisons undertaken with multiple t tests or non-parametric equivalents rather than with analysis of variance (ANOVA) or non-parametric equivalents.
- Post hoc tests being used following an ANOVA which has yielded a non-significant result.
- Incomplete names for tests (e.g. stating "Student's t test" without qualifying it by stating "single sample", "paired" or "independent sample")
- n values being given in a way which obscures how many independent samples there were (e.g. stating simply n=50 when 10 samples/measurements were obtained from each of 5 animals/human subjects).
- Stating that P=0.000 (a figure which is generated by some computer packages). The correct statement (in this case) is P<0.0005.
- Bar charts should only be used to show frequencies (absolute or relative/%); for means and SD, use dot plots and/or error bars.

### **Acknowledgements**

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.) but who did not meet all the criteria for authorship (see Authorship section above).

### **Formatting of funding sources**

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

---

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, it is recommended to include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### **Bacterial nomenclature**

Organisms should be referred to by their scientific names according to the binomial system. When first mentioned the name should be spelt in full and in italics. Afterwards the genus should be abbreviated to its initial letter, e.g. '*S. aureus*' not '*Staph. aureus*'. If abbreviation is likely to cause confusion or render the intended meaning unclear, the names of microbes should be spelt in full. Only those names which were included in the Approved List of Bacterial Names, *Int J Syst Bacteriol* 1980; 30: 225-420 and those which have been validly published in the *Int J Syst Bacteriol* since 1 January 1980 have standing in nomenclature. If there is good reason to use a name that does not have standing in nomenclature, the names should be enclosed in quotation marks and an appropriate statement concerning the nomenclatural status of the name should be made in the text (for an example see *Int J Syst Bacteriol* 1980; 30: 547-556). When the genus alone is used as a noun or adjective, use lower case Roman not italic, e.g. 'organisms were staphylococci' and 'streptococcal infection'. If the genus is specifically referred to use italics e.g. 'organisms of the genus *Staphylococcus*'. For genus in plural, use lower case roman e.g. '*salmonellae*'; plurals may be anglicized e.g. '*salmonellas*'. For trivial names, use lower case Roman e.g. '*meningococcus*'

### **Artwork**

#### *Image manipulation*

Whilst it is accepted that authors sometimes need to manipulate images for clarity, manipulation for purposes of deception or fraud will be seen as scientific ethical abuse and will be dealt with accordingly. For graphical images, this journal is applying the following policy: no specific feature within an image may be enhanced, obscured, moved, removed, or introduced. Adjustments of brightness, contrast, or color balance are acceptable if and as long as they do not obscure or eliminate any information present in the original. Nonlinear adjustments (e.g. changes to gamma settings) must be disclosed in the figure legend.

#### *Electronic artwork*

##### *General points*

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the published version.
- Submit each illustration as a separate file.
- Ensure that color images are accessible to all, including those with impaired color vision.

A detailed [guide on electronic artwork](#) is available.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

#### *Formats*

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

**Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

### Tables

Please submit tables as editable text and not as images. Tables should be placed on separate page(s) towards the end of the manuscript (see Manuscript Structure, above). Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

### Data references

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

### Preprint references

Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the name of the preprint server, as part of the reference. The preprint DOI should also be provided.

### Reference management software

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support [Citation Style Language styles](#), such as [Mendeley](#). Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. [More information on how to remove field codes from different reference management software.](#)

### Reference style

**Text:** Citations in the text should follow the referencing style used by the American Psychological Association. You are referred to the Publication Manual of the American Psychological Association, Seventh Edition, ISBN 978-1-4338-3215-4, copies of which may be [ordered online](#).

**List:** references should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication.

### Examples:

Reference to a journal publication:

Van der Geer, J., Hanraads, J. A. J., & Lupton, R. A. (2010). The art of writing a scientific article. *Journal of Scientific Communications*, 163, 51–59. <https://doi.org/10.1016/j.sc.2010.00372>.

Reference to a journal publication with an article number:

Van der Geer, J., Hanraads, J. A. J., & Lupton, R. A. (2018). The art of writing a scientific article. *Heliyon*, 19, Article e00205. <https://doi.org/10.1016/j.heliyon.2018.e00205>.

Reference to a book:

Strunk, W., Jr., & White, E. B. (2000). *The elements of style* (4th ed.). Longman (Chapter 4).

Reference to a chapter in an edited book:

Mettam, G. R., & Adams, L. B. (2009). How to prepare an electronic version of your article. In B. S. Jones, & R. Z. Smith (Eds.), *Introduction to the electronic age* (pp. 281–304). E-Publishing Inc.

Reference to a website:

Powertech Systems. (2015). *Lithium-ion vs lead-acid cost analysis*. Retrieved from <http://www.powertechsystems.eu/home/tech-corner/lithium-ion-vs-lead-acid-cost-analysis/>. Accessed January 6, 2016

Reference to a dataset:

---

[dataset] Oguro, M., Imahiro, S., Saito, S., & Nakashizuka, T. (2015). *Mortality data for Japanese oak wilt disease and surrounding forest compositions*. Mendeley Data, v1. <https://doi.org/10.17632/xwj98nb39r.1>.

Reference to a conference paper or poster presentation:

Engle, E.K., Cash, T.F., & Jarry, J.L. (2009, November). *The Body Image Behaviours Inventory-3: Development and validation of the Body Image Compulsive Actions and Body Image Avoidance Scales*. Poster session presentation at the meeting of the Association for Behavioural and Cognitive Therapies, New York, NY.

Reference to software:

Coon, E., Berndt, M., Jan, A., Svyatsky, D., Atchley, A., Kikinon, E., Harp, D., Manzini, G., Shelef, E., Lipnikov, K., Garimella, R., Xu, C., Moulton, D., Karra, S., Painter, S., Jafarov, E., & Molins, S. (2020, March 25). *Advanced Terrestrial Simulator (ATS) v0.88 (Version 0.88)*. Zenodo. <https://doi.org/10.5281/zenodo.3727209>.

### **Data visualization**

Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions [here](#) to find out about available data visualization options and how to include them with your article.

### **Research data**

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data](#) page.

### **Data linking**

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article.

When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#). For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

### **Mendeley Data**

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to *Mendeley Data*. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

### **Research Elements**

This journal enables you to publish research objects related to your original research – such as data, methods, protocols, software and hardware – as an additional paper in Research Elements.

---

Research Elements is a suite of peer-reviewed, open access journals which make your research objects findable, accessible and reusable. Articles place research objects into context by providing detailed descriptions of objects and their application, and linking to the associated original research articles. Research Elements articles can be prepared by you, or by one of your collaborators.

During submission, you will be alerted to the opportunity to prepare and submit a Research Elements article.

More information can be found on the [Research Elements page](#).

#### *Data statement*

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

### **AFTER ACCEPTANCE**

#### **Online proof correction**

To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

#### **Offprints**

The corresponding author will, at no cost, receive a customized [Share Link](#) providing 50 days free access to the final published version of the article on [ScienceDirect](#). The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

### **AUTHOR INQUIRIES**


Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).

© Copyright 2018 Elsevier | <https://www.elsevier.com>

## ANEXO 2 – Comitê de ética

---



Ofício CEEA-064/2017

Uberaba, 21 de novembro de 2017

Ilma Profa.

**Renata Oliveira Samuel**

**Assunto:** Encaminha processo nº 023/2017, sobre o protocolo de pesquisa "*Balanço imunorregulatório de células Th1/Th17/Treg em periodontites apicais de ratos normoglicêmicos e diabéticos*".

Prezado(a) Professor(a),

Em resposta a sua solicitação, informo que o protocolo acima referido foi submetido avaliação do CEEA-UNIUBE, na reunião do dia 23/10/2017, sendo considerado **aprovado**.

Atenciosamente,



**Prof. Jany F. Figueiredo Bittar**

Coordenadora do CEEA-UNIUBE